tetano
Editor, Senior Moderator
J Clin Microbiol. 2017 May 24. pii: JCM.00318-17. doi: 10.1128/JCM.00318-17. [Epub ahead of print]
[h=1]Multicenter Clinical Evaluation of the Luminex ARIES? Flu A/B & RSV Assay for pediatric and adult respiratory tract specimens.[/h] Juretschko S[SUP]1[/SUP], Mahony J[SUP]2[/SUP], Buller RS[SUP]3[/SUP], Manjj R[SUP]4[/SUP], Dunbar S[SUP]5[/SUP], Walker K[SUP]6[/SUP], Rao A[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A and B viruses and respiratory syncytial virus (RSV) are three common viruses implicated in seasonal respiratory tract infections and a major cause of morbidity and mortality in adults and children worldwide. In recent years, an increasing number of commercial molecular tests have become available to diagnose respiratory viral infections. The Luminex? ARIES? Flu A/B & RSV Assay is a fully automated sample-to-answer molecular diagnostic assay for the detection of influenza A, influenza B and RSV. The clinical performance of the ARIES? Flu A/B & RSV Assay was prospectively evaluated in comparison to the Luminex xTAG? Respiratory Viral Panel (RVP) at four North American clinical institutions over a two-year period. Of the 2479 eligible nasopharyngeal swab specimens included in the prospective study, 2371 gave concordant results between assays. 108 specimens generated results that were discordant with xTAG? RVP and further analyzed by bidirectional sequencing. Final clinical sensitivity values of the ARIES? Flu A/B & RSV Assay were 98.1% for influenza A, 98.0% for influenza B and 97.7% for RSV. Final clinical specificities for all three pathogens ranged from 98.6% to 99.8%. Due to low prevalence of influenza B, an additional 40 banked influenza B positive specimens were tested at the participating clinical laboratories and were all accurately detected by the ARIES? Flu A/B & RSV Assay. This study demonstrates that the ARIES? Flu A/B & RSV Assay is a suitable method for rapid and accurate identification of these causative pathogens in respiratory infections.
Copyright ? 2017 Juretschko et al.
PMID: 28539342 DOI: 10.1128/JCM.00318-17
[h=1]Multicenter Clinical Evaluation of the Luminex ARIES? Flu A/B & RSV Assay for pediatric and adult respiratory tract specimens.[/h] Juretschko S[SUP]1[/SUP], Mahony J[SUP]2[/SUP], Buller RS[SUP]3[/SUP], Manjj R[SUP]4[/SUP], Dunbar S[SUP]5[/SUP], Walker K[SUP]6[/SUP], Rao A[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A and B viruses and respiratory syncytial virus (RSV) are three common viruses implicated in seasonal respiratory tract infections and a major cause of morbidity and mortality in adults and children worldwide. In recent years, an increasing number of commercial molecular tests have become available to diagnose respiratory viral infections. The Luminex? ARIES? Flu A/B & RSV Assay is a fully automated sample-to-answer molecular diagnostic assay for the detection of influenza A, influenza B and RSV. The clinical performance of the ARIES? Flu A/B & RSV Assay was prospectively evaluated in comparison to the Luminex xTAG? Respiratory Viral Panel (RVP) at four North American clinical institutions over a two-year period. Of the 2479 eligible nasopharyngeal swab specimens included in the prospective study, 2371 gave concordant results between assays. 108 specimens generated results that were discordant with xTAG? RVP and further analyzed by bidirectional sequencing. Final clinical sensitivity values of the ARIES? Flu A/B & RSV Assay were 98.1% for influenza A, 98.0% for influenza B and 97.7% for RSV. Final clinical specificities for all three pathogens ranged from 98.6% to 99.8%. Due to low prevalence of influenza B, an additional 40 banked influenza B positive specimens were tested at the participating clinical laboratories and were all accurately detected by the ARIES? Flu A/B & RSV Assay. This study demonstrates that the ARIES? Flu A/B & RSV Assay is a suitable method for rapid and accurate identification of these causative pathogens in respiratory infections.
Copyright ? 2017 Juretschko et al.
PMID: 28539342 DOI: 10.1128/JCM.00318-17